IP Library Granted Patent US 12692317
Granted Patent B2
US 12692317 · App. 18/017,531 · Granted Jul 28, 2026

IL12RB2 binding molecules and methods of use

Inventors: Sandro Vivona (Menlo Park, CA); Robert Kastelein (Menlo Park, CA); Deepti Rokkam (Menlo Park, CA); Patrick J. Lupardus (Menlo Park, CA)
Assignee: Synthekine, Inc.
C07K16/2866A61P37/02C07K14/7155C07K16/2803C07K16/46C07K16/468C07K19/00C12N15/63C12N15/86A61K2039/505C07K2317/22C07K2317/24C07K2317/31C07K2317/33C07K2317/522C07K2317/524C07K2317/526C07K2317/53C07K2317/565C07K2317/567C07K2317/569C07K2319/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12692317
App. No.
18/017,531
Granted
Jul 28, 2026
Kind
B2
Abstract

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL12Rb2, compositions comprising such antibodies, and methods of use thereof.

Claims (226)

1 . A IL12Rb2 binding molecule that specifically binds to the extracellular domain of IL12Rb2, wherein the IL12Rb2 binding molecule comprises a single domain antibody (sdAb), wherein the sdAb comprises a complementary determining region 1 (CDR1), a CDR2, and a CDR3 as shown in a row of the table below:

CDR1

CDR2

CDR3

FTVTRYC

IIERDGRTGY

IEGSCRP

MG

ADSVKG

DFGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 20)

NO: 21)

NO: 22)

FTISRYC

IIERDGRTGY

IEGSCRPD

MG

ADSVKG

FGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 23)

NO: 24)

NO: 25)

LTFDDVE

SINTDSRVYY

DPWGGDLR

MA

VDSVKD

GYPNY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 26)

NO: 27)

NO: 28)

FTISRYC

IIERDGRTGY

IEGSCRPD

MG

ADSVKG

FGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 29)

NO: 30)

NO: 31)

FTFSTYA

RISSGGGNTY

DDYYGGSW

MS

YADAVKG

HPIS

(SEQ ID

(SEQ ID

(SEQ ID

NO: 32)

NO: 33)

NO: 34)

YTYGLFC

VVDSPGGRHV

DPEKYCFL

MG

ADSLKG

FSDAGYQY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 35)

NO: 36)

NO: 37)

VTYSRYC

TIYSRGIITY

TRETYG

MG

YTDSVKG

GSG

(SEQ ID

(SEQ ID

DCDYESV

NO: 38)

NO: 39)

YNY

(SEQ ID

NO: 40)

FTVSRYC

IIEREGRTGY

IEGSCRPD

MG

ADSVKG

FGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 41)

NO: 42)

NO: 43)

FTISRYC

IIERDGRTGY

IEGSCRPD

MG

ADSVKG

FGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 44)

NO: 45)

NO: 46)

FTVTRYC

IIERDGRTGY

IEGSCRPD

MG

ADSVKG

FGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 47)

NO: 48)

NO: 49)

FTVSRY

IIERDGRTGY

IEGSCRPD

CMG

ADSVKG

FGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 50)

NO: 51)

NO: 52)

VTYSRYCMG

TIYSRGI

TRETYGGS

(SEQ ID

ITYYTDS

GDCDYES

NO: 53)

VKG

VYNY

(SEQ ID

(SEQ ID

NO: 54)

NO: 55)

FTISKYC

IIERDGRTG

IEGSCRPD

MG

YADSVKG

FGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 56)

NO: 57)

NO: 58)

VTYSRYCMG

HIYSRGI

TRETYGGS

(SEQ ID

ITYYTDS

GDCGYESV

NO: 59)

VKG

YNY

(SEQ ID

(SEQ ID

NO: 60)

NO: 61)

FTISRYC

IIERDGRTGYA

IEGSCRP

MG

DSVKG

DLGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 62)

NO: 63)

NO: 64)

VTYSRYCMG

HIYSRGIITY

TRETYGGSGD

(SEQ ID

YTDSVKG

CSYESVYNH

NO: 65)

(SEQ ID

(SEQ ID

NO: 66)

NO: 67)

LTISRYC

IIERDGRTGYA

IEGSCRP

MG

DSVKG

DFGY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 68)

NO: 69)

NO: 70)

FTVDDFA

TISSGGSTYYA

SSVGCPL

MG

DSVKG

GY

(SEQ ID

(SEQ ID

(SEQ ID

NO: 71)

NO: 72)

NO: 73)

2 . The IL12Rb2 binding molecule of claim 1 wherein the sdAb has at least 80% identity to a polypeptide sequence of any one of SEQ ID NOS: 2-19.

3 . The IL12Rb2 binding molecule of claim 1 , wherein the sdAb is humanized or otherwise comprises CDRs grafted onto a heterologous framework.

4 . The IL12Rb2 binding molecule of claim 1 , further comprising a labeling agent, an imaging agent, and/or a therapeutic agent.